Fairscale Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Fairscale Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$928	Buy	+1	New	+$756	﹤0.01%	446

Other funds holding REGN

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

Fairscale Capital's REGN Position: Q3 2026 in Review

Fairscale Capital opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2026: 1 share worth $928. The stake represents ﹤0.01% of the portfolio and ranks #446 among its holdings.

755 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

Fairscale Capital held 1 share of Regeneron Pharmaceuticals worth $928 as of Q3 2026.
Regeneron Pharmaceuticals was a new Fairscale Capital position in Q3 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of Fairscale Capital's portfolio in Q3 2026, its #446 holding.
755 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Fairscale Capital's 13F filing for Q3 2026, filed 4 Nov 2026.